• Facebook
  • Twitter
  • LinkedIn
  • Google +
  • RSS

Genital herpes - Articles and news items

HerpV and GEN-003 will drive genital herpes treatment market growth to 2023, says GlobalData

Industry news / 21 July 2015 / Victoria White

The global market value for genital herpes therapeutics will increase from around $490 million in 2013 to just under $668 million by 2023, says GlobalData…

Genocea announces positive top-line data from Phase 2 GEN-003 optimisation trial

Industry news / 20 May 2015 / Victoria White

Genocea Biosciences has announced positive top-line data from a Phase 2 dose optimisation trial evaluating GEN-003 for the treatment of genital herpes…

Genocea’s GEN-003 in prime position to lead genital herpes vaccine space, says GlobalData Analyst

Industry news / 30 April 2015 / Victoria White

Genocea’s GEN-003 is better positioned to compete in the future genital herpes treatment space, despite being slightly behind Agenus’ HerpV in development…

Herpes Simplex Virus 1 (HSV-1) capsid

New Genital Herpes vaccine entrants require improved efficacy to compete, says GlobalData analyst

Industry news / 31 October 2014 / GlobalData

While the collaboration between Sanofi Pasteur (Sanofi) and Immune Design to develop a genital herpes vaccine presents a strong scientific foundation and difficult-to-match financial clout, the partnership needs to create a product with better clinical performance to compete with more advanced pipeline vaccine candidates, says an analyst with research and consulting firm GlobalData.